Phospholipid binding lowers immunogenicity of human recombinant factor VIII in von Willebrand factor knockout mice

• References

• 1 Klinge J, Ananyeva NM, Hauser CA. et al. Hemophilia A--from basic science to clinical practice. Semin Thromb Hemost 2002; 28: 309-322.
• 2 Pratt KP, Thompson AR. B-cell and T-cell epitopes in anti-factor VIII immune responses. Clin Rev Allergy Immunol 2009; 37: 80-95.
• 3 Ananyeva NM, Lacroix-Desmazes S, Hauser CA. et al. Inhibitors in hemophilia A: mechanisms of inhibition, management and perspectives. Blood Coagul Fibrinolysis 2004; 15: 109-124.
• 4 Jacquemin MG, Saint-Remy JM. Factor VIII immunogenicity. Haemophilia 1998; 4: 552-557.
• 5 Skupsky J, Zhang AH, Su Y. et al. A role for thrombin in the initiation of the immune response to therapeutic factor VIII. Blood 2009; 114: 4741-4748.
• 6 Behrmann M, Pasi J, Saint-Remy JMR. et al. Von Willebrand factor modulates factor VIII immunogenicity: Comparative study of different factor VIII concentrates in a haemophilia A mouse model. Thromb Haemost 2002; 88: 221-229.
• 7 Delignat S, Dasgupta S, Andre S. et al. Comparison of the immunogenicity of different therapeutic preparations of human factor VIII in the murine model of hemophilia A. Haematologica 2007; 92: 1423-1426.
• 8 Qadura M, Waters B, Burnett E. et al. Recombinant and plasma-derived factor VIII products induce distinct splenic cytokine microenvironments in hemophilia A mice. Blood 2009; 114: 871-880.
• 9 Dasgupta S, Repesse Y, Bayry J. et al. VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. Blood 2007; 109: 610-612.
• 10 Navarrete AM, Dasgupta S, Teyssandier M. et al. Endocytic receptor for procoagulant factor VIII: relevance to inhibitor formation. Thromb Haemost 2010; 104: 1093-1098.
• 11 Lacroix-Desmazes S, Repesse Y, Kaveri SV. et al. The role of VWF in the immunogenicity of FVIII. Thrombosis Res 2008; 122: S3-S6.
• 12 Meeks SL, Healey JF, Parker ET. et al. Antihuman factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation. Blood 2007; 110: 4234-4242.
• 13 Pratt KP, Qian J, Ellaban E. et al. Immunodominant T-cell epitopes in the factor VIII C2 domain are located within an inhibitory antibody binding site. Thromb Haemost 2004; 92: 522-528.
• 14 Saenko EL, Scandella D. The acidic region of the factor VIII light chain and the C2 domain together form the high affinity binding site for von willebrand factor. J Biol Chem 1997; 272: 18007-18014.
• 15 Pisal DS, Balu-Iyer SV. Phospholipid binding improves plasma survival of factor VIII. Thromb Haemost 2010; 104: 1073-1075.
• 16 Kaveri SV, Dasgupta S, Andre S. et al. Factor VIII inhibitors: role of von Willebrand factor on the up-take of factor VIII by dendritic cells. Haemophilia 2007; 13: 61-64.
• 17 Peng A, Straubinger RM, Balu-Iyer SV. Phosphatidylinositol containing lipidic particles reduces immunogenicity and catabolism of factor VIII in hemophilia a mice. AAPS J 2010; 12: 473-481.
• 18 Ramani K, Miclea RD, Purohit VS. et al. Phosphatidylserine containing liposomes reduce immunogenicity of recombinant human factor VIII (rFVIII) in a murine model of hemophilia A. J Pharm Sci 2008; 97: 1386-1398.
• 19 Purohit VS, Ramani K, Sarkar R. et al. Lower inhibitor development in hemophilia A mice following administration of recombinant factor VIIIO-phospho-L-serine complex. J Biol Chem 2005; 280: 17593-17600.
• 20 Verbruggen B, van Heerde WL, Laros-van Gorkom BA. Improvements in factor VIII inhibitor detection: From Bethesda to Nijmegen. Semin Thromb Hemost 2009; 35: 752-759.
• 21 Lutz MB, Kukutsch N, Ogilvie AL. et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 1999; 223: 77-92.